COVID-19 Evidence Alerts
from McMaster PLUSTM

Current best evidence for clinical care (more info)

COVID-19 Evidence Alerts needs your support. If our service is of value to you, please consider donating to keep it going. Learn more Donate now

Treatment Huang M, Tang T, Pang P, et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol. 2020 May 18;12(4):322-325. doi: 10.1093/jmcb/mjaa014.
Discipline / Specialty Area Score
Family Medicine (FM)/General Practice (GP)
General Internal Medicine-Primary Care(US)
Hospital Doctor/Hospitalists
Internal Medicine
Comments from MORE raters

General Internal Medicine-Primary Care(US) rater

The absence of a control group (no treatment/placebo) makes it impossible to determine whether chloroquine is efficacious or if treatment with lopinavir/ritonavir is harmful.

Hospital Doctor/Hospitalists rater

Too small and preliminary to be actionable.

Hospital Doctor/Hospitalists rater

A small sample size with early initiation of chloroquine. Unclear whether chloroquine actually provides benefit. Repeat study is needed with similar time of initiation of control vs chloroquine to evaluate for efficacy.

Internal Medicine rater

Adds to the evidence on this controversial topic, although the study is small and biases are quite likely. I find it notable that the authors fail to discuss imbalances in the baseline characteristics of the groups including age (CQ patients > 10 years younger on average) and shorter disease duration in CQ group.

Internal Medicine rater

Ridiculously small case series - 22 patients. This is of no use at all.